|
Introduction
The Auburn University Hybridoma
Facility has been providing services for the development of
hybridoma cell lines producing murine monoclonal antibodies
specific for given antigens since 1989. During this period
over 97% of the hybridoma projects initiated at our facility
have been successfully completed. Antibodies from the cell
lines produced have been used in both applied and basic
research. Our facility is pleased to provide services for
the production of monoclonal antibodies to both faculty and
students resident at Auburn University, and to investigators
at other institutions or in private industry.Our off-campus service center provides
an extremely efficient environment that is conducive to
uninterrupted research. Separate laboratories are available
for a) culture medium preparation, b) mouse preparation and
dissection, c) cell culture and hybridoma fusion, and d)
hybridoma screening, as well as rooms for autoclaving and
water treatment and a mouse rearing facility that meets NIH
guidelines.
You provide the antigen or antigenic
material of choice and our trained personnel will perform
all phases of hybridoma development and monoclonal antibody
production, including mouse immunization, cell fusion, HAT
selection of hybridoma cell lines, ELISA or western blot
screening of hybridoma cell lines for specific antibodies,
cloning, frozen storage of cell lines, and ascites antibody
production. Currently the cost of an average academic
hybridoma project is about $1500.00, though cost may vary
depending on what services are required (see fee schedules).
Where desired, our flexible program,
that combines service and instruction, allows us to arrange
for investigators, technicians, or students to participate
as trainees in all the facets of hybridoma development. In
such instances, it is possible to gain an in-depth, working
knowledge of monoclonal production techniques.
Without exception, investigators and
students who have used the Hybridoma Facility compliment its
efficient management and high success rate in producing
desired monoclonal antibodies. |
